Prophylactic Administration of Surfactant in Extremely Premature Infants

Overview

Journal Crit Care Res Pract

Publisher Wiley

Specialty Critical Care

Date 2010 Oct 16

PMID 20948885

Citations 1

Authors

Lutz Koch

David Frommhold

Bernd Beedgen

Peter Ruef

Johannes Poeschl

Affiliations

Soon will be listed here.

Abstract

Objective. To investigate whether prophylactic surfactant administration is superior over selective treatment in preterm infants with respiratory distress syndrome (RDS). Methods. In our retrospective analysis, we compared premature infants (23 + 0 to 26 + 6 weeks) receiving 200 mg/kg surfactant (curosurf(®)) within five minutes after birth (prophylactic group, N = 31) with those infants who received surfactant therapy for established RDS (selective group, N = 34). Results. Prophylactic therapy significantly decreased the need for mechanical ventilation (74 hours per patient versus 171 hours per patient, resp.). We observed a reduced incidence of interstitial emphysema (0% versus 9%, resp.), pneumothoraces (3% versus 9%, resp.), chronic lung disease (26% versus 38%, resp.), and surfactant doses per patient (1.3 versus 1.8, resp.), although those variables did not reach significance. Conclusion. We conclude that infants under 27 weeks' gestation profit from prophylactic surfactant administration by reducing the time of mechanical ventilation. This in turn could contribute to reduce the risk for mechanical ventilation associated complications, without any detrimental short-term side effects.

Citing Articles

Intubation-Surfactant: Extubation on Continuous Positive Pressure Ventilation. Who are the Best Candidates?.

Ognean M, Stoicescu S, Boanta O, Nastase L, Gliga C, Cucerea M J Crit Care Med (Targu Mures). 2018; 2(2):73-79.

PMID: 29967841 PMC: 5939130. DOI: 10.1515/jccm-2016-0010.

References

Merritt T, Hallman M, Holcomb K, Strayer D, Bloom B, Revak S . Human surfactant treatment of severe respiratory distress syndrome: pulmonary effluent indicators of lung inflammation. J Pediatr. 1986; 108(5 Pt 1):741-8. DOI: 10.1016/s0022-3476(86)81058-7. View

Horbar J, Carpenter J, Buzas J, Soll R, Suresh G, Bracken M . Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based?. Pediatrics. 2004; 113(6):1593-602. DOI: 10.1542/peds.113.6.1593. View

Ikegami M, Jacobs H, Jobe A . Surfactant function in respiratory distress syndrome. J Pediatr. 1983; 102(3):443-7. DOI: 10.1016/s0022-3476(83)80673-8. View

Sandri F, Ancora G, Lanzoni A, Tagliabue P, Colnaghi M, Ventura M . Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial. Arch Dis Child Fetal Neonatal Ed. 2004; 89(5):F394-8. PMC: 1721765. DOI: 10.1136/adc.2003.037010. View

Kendig J, Notter R, Cox C, Reubens L, Davis J, Maniscalco W . A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med. 1991; 324(13):865-71. DOI: 10.1056/NEJM199103283241301. View

Kresch M, Clive J . Meta-analyses of surfactant replacement therapy of infants with birth weights less than 2000 grams. J Perinatol. 1998; 18(4):276-83. View

Grossmann G, Nilsson R, Robertson B . Scanning electron microscopy of epithelial lesions induced by artificial ventilation of the immature neonatal lung; the prophylactic effect of surfactant replacement. Eur J Pediatr. 1986; 145(5):361-7. DOI: 10.1007/BF00439239. View

Sweet D, Bevilacqua G, Carnielli V, Greisen G, Plavka R, Saugstad O . European consensus guidelines on the management of neonatal respiratory distress syndrome. J Perinat Med. 2007; 35(3):175-86. DOI: 10.1515/JPM.2007.048. View

Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanocka U . Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr. 2005; 147(3):341-7. DOI: 10.1016/j.jpeds.2005.04.062. View

10.

Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrom K . Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med. 1994; 331(16):1051-5. DOI: 10.1056/NEJM199410203311603. View

11.

Ikegami M, Jobe A, SEIDNER S, Yamada T . Gestational effects of corticosteroids and surfactant in ventilated rabbits. Pediatr Res. 1989; 25(1):32-7. DOI: 10.1203/00006450-198901000-00007. View

12.

Jobe A, Ikegami M, Jacobs H, Jones S, Conaway D . Permeability of premature lamb lungs to protein and the effect of surfactant on that permeability. J Appl Physiol Respir Environ Exerc Physiol. 1983; 55(1 Pt 1):169-76. DOI: 10.1152/jappl.1983.55.1.169. View

13.

Stevens T, Harrington E, Blennow M, Soll R . Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007; (4):CD003063. PMC: 8554819. DOI: 10.1002/14651858.CD003063.pub3. View

14.

Finer N, Carlo W, Duara S, Fanaroff A, Donovan E, Wright L . Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial. Pediatrics. 2004; 114(3):651-7. DOI: 10.1542/peds.2004-0394. View

15.

Soll R, Morley C . Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000; (2):CD000510. DOI: 10.1002/14651858.CD000510. View

16.

Reininger A, Khalak R, Kendig J, Ryan R, Stevens T, Reubens L . Surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial. J Perinatol. 2005; 25(11):703-8. DOI: 10.1038/sj.jp.7211381. View

17.

Bevilacqua G, Parmigiani S, Robertson B . Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial. J Perinat Med. 1996; 24(6):609-20. DOI: 10.1515/jpme.1996.24.6.609. View

18.

Halliday H . Recent clinical trials of surfactant treatment for neonates. Biol Neonate. 2006; 89(4):323-9. DOI: 10.1159/000092869. View

19.

Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F . Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics. 1997; 100(1):E4. DOI: 10.1542/peds.100.1.e4. View

20.

Gastmeier P, Geffers C, Schwab F, Fitzner J, Obladen M, Ruden H . Development of a surveillance system for nosocomial infections: the component for neonatal intensive care units in Germany. J Hosp Infect. 2004; 57(2):126-31. DOI: 10.1016/j.jhin.2003.12.038. View